Clinical Trials

Urinary Tract/Bladder Cancer Trials

Learn More About Our Urinary Tract/Bladder Cancer Trials

  • 1 PCYC-1128-CA Show More

    PCYC-1128-CA – A Phase1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (Bladder, Colon,Gastric,Renal)

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Advanced GU Cancer (Bladder and Renal)

    2. WHO IS ELIGIBLE?
    Patients who have received prior chemothreapy .

    3. HOW WILL I BE TREATED?
    Patients will receive Ibrutinib with other chemotherapy or biologic therapy .

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 2 S1605 Show More

    S1605 – Phase II Trial of Atezolizumab in BCG-Unresponsive Non- Muscle Invasive Bladder Cancer.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Early bladder Cancer.

    2. WHO IS ELIGIBLE?
    Men with bladder cancer who have received BCG.

    3. HOW WILL I BE TREATED?
    Atezolizumab, an immunotherapy that acts on PDL1.

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 3 A031701 Show More

    A031701 – A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Bladder Cancer.

    2. WHO IS ELIGIBLE?
    Patients must have muscle-invasive bladder cancer. They will be tested for a DDR mutation.

    3. HOW WILL I BE TREATED?
    This study looks at treating with chemotherapy for bladder preservation.

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 4 A031501 Show More

    A031501 – Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Urothelial cancers (Bladder, Ureter, or Kidney).

    2. WHO IS ELIGIBLE?
    Patients who have had complete resection (TURBT that completely removed tumor is okay).

    3. HOW WILL I BE TREATED?
    The study looks at treating with Pembrolizumab, an anti-PD-1 immunotherapy.

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 5 S1602 Show More

    S1602 – A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Bladder care (no prior treatment)

    2. WHO IS ELIGIBLE?
    High-grade muscle-invasive bladder cancer.

    3. HOW WILL I BE TREATED?
    This study evaluates the effect of adding a vaccine to BCG therapy.

    For Physicians: More information about this specific trial at clinicaltrials.gov

EJGH Trials Send an Inquiry

Click here